MSD is advancing its once-monthly oral pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) to Phase III ...

Health leaders at the International AIDS Society (IAS) 2025 conference in Kigali have warned that shrinking funding and ...

Cabenuva is administered every two months and was offered to patients who achieved viral suppression from daily treatments.

As science soars with game-changing HIV tools, a funding crisis threatens to ground progress "We come together at a pivotal time for the HIV response, one defined by both incredible scientific ...

In a major advancement in the global fight against HIV, the World Health Organization (WHO) has recommended the use of ...

Kyrgyzstan's official silence on a rapidly growing cryptocurrency exchange, Grinex, is raising international concerns about ...

Lenacapavir, a long-acting injectable pre-exposure prophylaxis, has been recommended by the WHO to help protect high-risk ...

A breakthrough HIV drug that only needs to be injected twice a year to offer near-total protection from the virus and ...

HIV pharma leaders are at Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the ...

LEN is the first long-acting PrEP product that requires only two injections per year, offering an appealing alternative to ...

Kenya has been selected as one of the 9 early adopter countries for the rollout of Lenacapavir (LEN), a long-acting ...

The global recommendation – issued Monday at the International AIDS Conference in Kigali, Rwanda – comes about a month after ...